Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology
Xi-Chun HuZhi-Min Shao

Abstract

Platinum chemotherapy has a role in the treatment of metastatic triple-negative breast cancer but its full potential has probably not yet been reached. We assessed whether a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. For this open-label, randomised, phase 3, hybrid-designed trial undertaken at 12 institutions or hospitals in China, we included Chinese patients aged 18-70 years with previously untreated, histologically confirmed metastatic triple-negative breast cancer, and an ECOG performance status of 0-1. These patients were randomly assigned (1:1) to receive either cisplatin plus gemcitabine (cisplatin 75 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8) or paclitaxel plus gemcitabine (paclitaxel 175 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8) given intravenously every 3 weeks for a maximum of eight cycles. Randomisation was done centrally via an interactive web response system using block randomisation with a size of eight, with no stratification factors. Patients and investigator were aware of group assignments. The primary endpoint was progression-free sur...Continue Reading

References

Nov 11, 2005·Journal of Biopharmaceutical Statistics·Tatsuki Koyama, Peter H Westfall
Apr 21, 2007·The Journal of Clinical Investigation·Chee-Onn LeongLeif W Ellisen
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Nov 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boris FreidlinRobert Gray
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy S AlbainJoyce O'Shaughnessy
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabrice AndreLajos Pusztai
Dec 22, 2009·American Journal of Clinical Oncology·Anthony D Elias
Oct 13, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E H LipsS Rodenhuis
Apr 21, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma
Dec 12, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y FanR G Cai
Dec 18, 2012·Breast Cancer Research and Treatment·Cynthia X MaPaula M Fracasso
Jul 31, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D W MilesJ O'Shaughnessy
Jan 31, 2014·Core Evidence·Otávio ClarkMariana Bhering Andrade Ferreira
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Ambedkar Raj Kulandai VeluIlavarasi Sinduja
Oct 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyEric P Winer

❮ Previous
Next ❯

Citations

Dec 17, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zhen-Hua WuXi-Chun Hu
Aug 25, 2015·Journal of Experimental & Clinical Cancer Research : CR·Bi-Yun WangXi-Chun Hu
Sep 28, 2015·Cancer Treatment Reviews·S D'OronzoF Silvestris
Sep 9, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Kenneth K Y LaiSimon Law
Mar 22, 2015·The Lancet Oncology·Lisa Carey
Aug 2, 2016·Expert Opinion on Drug Delivery·Fanfei MengYoon Yeo
Dec 24, 2015·Current Opinion in Obstetrics & Gynecology·Sara Hurvitz, Monica Mead
Oct 6, 2017·Genes·Nancy Martínez-MontielRebeca D Martínez-Contreras
Dec 3, 2017·Pain and Therapy·Vasiliki BrozouPanagiotis Zis
Jan 5, 2019·Journal of Biomaterials Science. Polymer Edition·Longyi PiaoJing Jiang
Jan 18, 2018·Expert Opinion on Pharmacotherapy·Palma FedeleSaverio Cinieri
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Carey K AndersRebecca Dent
Apr 5, 2020·Breast Cancer Research and Treatment·Takehiro HiraiMasaaki Matsuura
May 6, 2016·Oncotarget·Yong HanDongsheng Huang
Oct 11, 2016·Journal of breast cancer·Sung Gwe AhnJoon Jeong
Aug 14, 2020·Frontiers of Medicine·Hongnan Mo, Binghe Xu
Jun 27, 2020·International Journal of Cancer. Journal International Du Cancer·Yimeng ChenYing Fan
Jul 15, 2015·Current Opinion in Supportive and Palliative Care·Lee Guek EngRebecca Dent
Jun 24, 2017·The Cochrane Database of Systematic Reviews·Sam J EggerNicholas Wilcken
Sep 19, 2018·International Journal of Molecular Medicine·Yang ZhangHaifeng Cai
Jun 4, 2019·The Breast Journal·Parham Khosravi-ShahiMaria Inmaculada Aparicio Salcedo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

© 2021 Meta ULC. All rights reserved